The Good Fiber Company · Data tracker

Who pays for weight-loss GLP-1s in Europe?

Whether GLP-1 medicines for weight loss (Wegovy, Mounjaro) are publicly funded, country by country. Every status is sourced to a national health-technology or payer body.

Status as of October 2026 · reviewed quarterly

Across 16 European countries, only 2 publicly fund GLP-1 medicines for weight loss, and one more funds them only through tight clinical gates. Almost everywhere else, patients pay out of pocket, several countries after their own agencies said no.

16
European countries tracked
2
publicly fund weight-loss GLP-1s
13
leave patients paying out of pocket
Filter
France
Publicly funded
First EU country. Wegovy and Mounjaro reimbursable for weight control since 15 June 2026, 65% base rate; BMI 40+, or 35+ with a listed comorbidity; initial prescription by obesity specialists.
Source: HAS · arrêtés/JO 2026
Switzerland
Publicly funded
Basic insurance covers Wegovy (since March 2024) and Mounjaro (since January 2026) for weight management under conditions: BMI 35 or more, or 28 or more with a weight-related condition; prescribed by specialists, with stop rules if weight loss falls short; about 90% after the deductible. Both listings are time-limited (Wegovy to end-February 2027, Mounjaro to end-2027).
Source: OKP · BAG (KLV)
United Kingdom
Restricted access
Not a reimbursement rate: the NHS commissions it through clinical gates. Wegovy via specialist weight-management services; Mounjaro phased into GP prescribing from March 2025. Outside the gates, patients pay privately.
Source: NICE (TA1026) · NHS England
Austria
Not publicly funded
Weight-loss medicines are 'fundamentally not reimbursable' under social-insurance law; a narrow special arrangement covers Wegovy only for particularly vulnerable patients after 6 months without success.
Source: ÖGK · Dachverband
Belgium
Not publicly funded
The health minister confirmed in 2026 that Wegovy will not be reimbursed, following the advice of the RIZIV/INAMI reimbursement committee.
Source: RIZIV-INAMI
Denmark
Not publicly funded
Not publicly subsidised for weight loss: the Danish Medicines Agency refused general reimbursement for Wegovy because its price is out of proportion to its treatment value. Out-of-pocket.
Source: Lægemiddelstyrelsen
Finland
Not publicly funded
Kela does not reimburse Wegovy; the pricing board rejected coverage on cost-benefit grounds. Only Saxenda and Mysimba get partial reimbursement.
Source: Kela · Hila
Germany
Not publicly funded
Excluded for weight loss as a 'lifestyle medicine' under section 34 SGB V. Reimbursed only in the type-2-diabetes indication.
Source: §34 SGB V · G-BA
Ireland
Not publicly funded
Wegovy and Mounjaro are not covered for weight loss; only Saxenda is funded, via an HSE managed-access protocol with strict criteria. Wegovy/Mounjaro are 'under review'.
Source: HSE
Italy
Not publicly funded
Wegovy, Saxenda and Mounjaro for weight are Class C (Fascia C): the patient pays. AIFA placed Wegovy in Band C on launch in July 2024.
Source: AIFA
Netherlands
Not publicly funded
The care institute advised against basic-package reimbursement of Wegovy for obesity (2024). A fresh assessment for the highest-need groups is under way, with no change yet.
Source: Zorginstituut Nederland
Norway
Not publicly funded
Not covered on the 'blue prescription' for obesity; individual funding only in very special cases. In November 2025 the medicines agency found Wegovy cost-effective for people with a BMI of 35 or more and at least two weight-related diseases, but funding needs a budget decision by parliament.
Source: DMP (Norway)
Poland
Not publicly funded
Not reimbursed by the national health fund; patients pay 100% for the obesity indication. A diabetes discount applies only to low doses.
Source: NFZ
Portugal
Not publicly funded
The medicines agency has not included Wegovy in public co-payment for obesity; no approved obesity medicine is reimbursed. An exceptional-reimbursement scheme is announced but not yet published.
Source: INFARMED
Spain
Not publicly funded
The public health system does not finance Wegovy/Mounjaro/Saxenda for obesity; the pricing commission (CIPM) rejected Wegovy three times on budget grounds. Diabetes indications are financed.
Source: CIPM · Min. de Sanidad
Sweden
Not publicly funded
The benefits agency (TLV) rejected subsidising Wegovy in February 2026, citing cost and indication-creep risk. Out-of-pocket.
Source: TLV
Cite this dataset
The Good Fiber Company (2026). Who pays for weight-loss GLP-1s in Europe?. https://goodfibercompany.com/glp1-weight-loss-coverage-europe/
Embed / link: https://goodfibercompany.com/glp1-weight-loss-coverage-europe/

Methodology

This tracks public funding for the obesity / weight-management indication only, using Wegovy (semaglutide) as the reference and noting Mounjaro (tirzepatide) where it differs. GLP-1 medicines prescribed for type-2 diabetes are broadly reimbursed across these countries and are a separate question this map does not cover. Each country is placed in one of three bands: publicly funded (the weight-loss indication is reimbursed, with clinical conditions), restricted access (funded only through tight clinical gates or a phased rollout), or not publicly funded (private-pay, with any narrow exception noted). Every status traces to a national health-technology assessment or payer body, listed below.

This is a sourced snapshot, not medical or reimbursement advice, and it moves fast: France began reimbursing in June 2026, and reviews are live in several countries. Check your national payer for your own situation. Reviewed quarterly; status current as of October 2026.

Reimbursement is a separate question from approval. For which oral GLP-1 pills are approved and on sale where, see Oral GLP-1 Pills in Europe.

Sources

  1. France: Haute Autorité de santé (HAS), Commission de la transparence; arrêtés du 10 juin 2026 (JO du 12 juin 2026); Service-public.fr: reimbursement of Wegovy and Mounjaro for weight control from 15 June 2026. link
  2. Switzerland: mandatory basic insurance (OKP) coverage of Wegovy (since March 2024) and Mounjaro (since January 2026) for weight management under specialty-list limitations (Federal Office of Public Health, BAG). link
  3. United Kingdom: NICE technology appraisal TA1026 (tirzepatide) and NICE guidance on semaglutide; NHS England interim commissioning guidance (phased primary-care rollout from 24 March 2025). link
  4. Germany: Section 34 SGB V (exclusion of 'Lifestyle-Arzneimittel'); Gemeinsamer Bundesausschuss (G-BA) Arzneimittel-Richtlinie. link
  5. Spain: Real Decreto Legislativo 1/2015, art. 92; decisions of the Comisión Interministerial de Precios de los Medicamentos (CIPM), Ministerio de Sanidad. link
  6. Italy: Agenzia Italiana del Farmaco (AIFA): Wegovy/Saxenda/Mounjaro for weight classified Fascia C (non-reimbursable). link
  7. Netherlands: Zorginstituut Nederland, GVS advice against reimbursing semaglutide (Wegovy) for obesity (12 July 2024); 2025 reassessment for highest-need groups. link
  8. Belgium: RIZIV-INAMI Commission for Reimbursement of Medicines; ministerial decision not to reimburse Wegovy (2026). link
  9. Denmark: Lægemiddelstyrelsen (Danish Medicines Agency) refusal of general reimbursement for Wegovy; not publicly subsidised for weight loss. link
  10. Sweden: Tandvårds- och läkemedelsförmånsverket (TLV) decision rejecting subsidy for Wegovy (23 February 2026). link
  11. Norway: Direktoratet for medisinske produkter (Norwegian Medical Products Agency): Wegovy not on the blue-prescription scheme for obesity; November 2025 cost-effectiveness finding for BMI 35+ with two weight-related diseases, pending a budget decision. link
  12. Finland: Kela and the Pharmaceuticals Pricing Board (Lääkkeiden hintalautakunta, Hila): no reimbursement for Wegovy in obesity. link
  13. Poland: Narodowy Fundusz Zdrowia (NFZ) reimbursement lists: Wegovy not reimbursed for obesity. link
  14. Ireland: Health Service Executive (HSE): Saxenda under a managed-access protocol; Wegovy and Mounjaro not covered for weight loss. link
  15. Austria: ÖGK / Dachverband der Sozialversicherungsträger: weight-loss medicines not reimbursable under the ASVG; limited Wegovy special arrangement. link
  16. Portugal: INFARMED: Wegovy not included in SNS comparticipação for obesity; exceptional-reimbursement scheme pending. link